New Market Research Report: Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022
GlobalData has released its new PharmaPoint Drug Evaluation report, "Synagis (Pediatric RSV) - Forecast and Market Analysis to 2022". Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission typically occurs during the winter and early spring months. The virus is spread through the air by an infected person's sneeze or cough, or through direct and indirect contact with nasal...
View full press release